Charles Duncan
Stock Analyst at Cantor Fitzgerald
(3.94)
# 665
Out of 4,412 analysts
183
Total ratings
35.32%
Success rate
15.39%
Average return
Main Sectors:
46 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Reiterates: Overweight | $120 | $73.26 | +63.80% | 13 | Apr 24, 2024 | |
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $7.94 | - | 2 | Apr 19, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Reiterates: Overweight | n/a | $38.97 | - | 8 | Apr 18, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Overweight | $49 | $29.32 | +67.12% | 7 | Apr 12, 2024 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $20.87 | - | 12 | Apr 10, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $155 | $135.99 | +13.98% | 6 | Apr 10, 2024 | |
| MRNS Marinus Pharmaceuticals | Reiterates: Overweight | $28 | $1.41 | +1,892.88% | 4 | Apr 10, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $180 | $109.46 | +64.44% | 3 | Apr 10, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $107 | $71.71 | +49.21% | 13 | Apr 10, 2024 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $37 | $16.71 | +121.42% | 12 | Apr 10, 2024 | |
| ATAI Atai Life Sciences | Reiterates: Overweight | n/a | $1.93 | - | 2 | Apr 4, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $12.41 | - | 5 | Apr 4, 2024 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $34 | $14.89 | +128.34% | 7 | Mar 22, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Neutral | $38 → $45 | $42.47 | +5.96% | 2 | Dec 7, 2023 | |
| DNLI Denali Therapeutics | Assumes: Overweight | $85 → $35 | $15.43 | +126.83% | 5 | Oct 24, 2023 | |
| CRNX Crinetics Pharmaceuticals | Assumes: Overweight | $52 → $50 | $42.12 | +18.71% | 3 | Oct 24, 2023 | |
| CYTK Cytokinetics | Maintains: Overweight | $59 → $65 | $65.34 | -0.52% | 5 | Oct 9, 2023 | |
| SLDB Solid Biosciences | Initiates: Overweight | $5 | $8.98 | -44.32% | 1 | Sep 22, 2023 | |
| SEEL Seelos Therapeutics | Downgrades: Neutral | n/a | $0.29 | - | 7 | Sep 21, 2023 | |
| VXRT Vaxart | Reiterates: Overweight | $4 | $0.71 | +463.62% | 4 | Sep 7, 2023 | |
| CYBN Cybin | Reiterates: Overweight | $3 | $0.35 | +757.14% | 4 | Aug 29, 2023 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $4 | $0.68 | +485.57% | 4 | Aug 22, 2023 | |
| XENE Xenon Pharmaceuticals | Reiterates: Overweight | $58 | $40.50 | +43.21% | 3 | Aug 22, 2023 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Overweight | $7 | $8.52 | -17.84% | 2 | Aug 22, 2023 | |
| LUMO Lumos Pharma | Reiterates: Overweight | $10 | $2.86 | +249.65% | 4 | Aug 22, 2023 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | $20 | $10.78 | +85.53% | 2 | Aug 22, 2023 | |
| BIVI BioVie | Reiterates: Overweight | $11 | $0.48 | +2,168.98% | 4 | Aug 22, 2023 | |
| CLNN Clene | Reiterates: Overweight | $4 | $0.34 | +1,076.82% | 5 | Aug 16, 2023 | |
| CRDL Cardiol Therapeutics | Reiterates: Overweight | $3 | $1.79 | +67.60% | 2 | Aug 14, 2023 | |
| AVXL Anavex Life Sciences | Downgrades: Neutral | $16 → $11 | $3.44 | +219.77% | 1 | Dec 6, 2022 | |
| FENC Fennec Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $9.21 | +30.29% | 2 | Nov 22, 2022 | |
| CGTX Cognition Therapeutics | Initiates: Overweight | $12 | $1.95 | +515.38% | 1 | Sep 29, 2022 | |
| NVAX Novavax | Maintains: Overweight | $146 → $168 | $4.09 | +4,007.58% | 6 | Jun 8, 2022 | |
| ORMP Oramed Pharmaceuticals | Initiates: Overweight | $20 | $2.46 | +713.01% | 1 | Feb 18, 2022 | |
| VTVT vTv Therapeutics | Initiates: Overweight | $200 | $26.97 | +641.70% | 3 | Feb 18, 2022 | |
| BNOX Bionomics | Initiates: Overweight | $52 | $1.00 | +5,100.00% | 1 | Jan 10, 2022 | |
| OVID Ovid Therapeutics | Downgrades: Neutral | n/a | $3.10 | - | 1 | Apr 20, 2021 | |
| SAVA Cassava Sciences | Initiates: Overweight | n/a | $22.34 | - | 1 | Oct 23, 2020 | |
| INO Inovio Pharmaceuticals | Downgrades: Neutral | $372 → $144 | $10.57 | +1,262.35% | 5 | Sep 28, 2020 | |
| GERN Geron | Maintains: Overweight | n/a | $3.79 | - | 1 | Jun 1, 2020 | |
| HALO Halozyme Therapeutics | Reiterates: Overweight | n/a | $38.57 | - | 2 | May 4, 2020 | |
| CARA Cara Therapeutics | Reiterates: Overweight | n/a | $0.68 | - | 1 | Apr 22, 2020 | |
| CORT Corcept Therapeutics | Downgrades: Neutral | n/a | $22.80 | - | 3 | Feb 1, 2019 | |
| VNDA Vanda Pharmaceuticals | Initiates: Neutral | n/a | $4.62 | - | 1 | Aug 23, 2018 | |
| SGMO Sangamo Therapeutics | Upgrades: Overweight | n/a | $0.52 | - | 1 | Nov 15, 2017 | |
| ALT Altimmune | Initiates: Overweight | n/a | $7.26 | - | 1 | Oct 9, 2017 |
Intra-Cellular Therapies
Apr 24, 2024
Reiterates: Overweight
Price Target: $120
Current: $73.26
Upside: +63.80%
COMPASS Pathways
Apr 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.94
Upside: -
Biohaven Pharmaceutical Holding Company
Apr 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.97
Upside: -
Harmony Biosciences Holdings
Apr 12, 2024
Reiterates: Overweight
Price Target: $49
Current: $29.32
Upside: +67.12%
Prothena Corporation
Apr 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.87
Upside: -
Neurocrine Biosciences
Apr 10, 2024
Reiterates: Overweight
Price Target: $155
Current: $135.99
Upside: +13.98%
Marinus Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $28
Current: $1.41
Upside: +1,892.88%
Jazz Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $180
Current: $109.46
Upside: +64.44%
Axsome Therapeutics
Apr 10, 2024
Reiterates: Overweight
Price Target: $107
Current: $71.71
Upside: +49.21%
ACADIA Pharmaceuticals
Apr 10, 2024
Reiterates: Overweight
Price Target: $37
Current: $16.71
Upside: +121.42%
Atai Life Sciences
Apr 4, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.93
Upside: -
Stoke Therapeutics
Apr 4, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.41
Upside: -
Catalyst Pharmaceuticals
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $14.89
Upside: +128.34%
Cerevel Therapeutics Holdings
Dec 7, 2023
Downgrades: Neutral
Price Target: $38 → $45
Current: $42.47
Upside: +5.96%
Denali Therapeutics
Oct 24, 2023
Assumes: Overweight
Price Target: $85 → $35
Current: $15.43
Upside: +126.83%
Crinetics Pharmaceuticals
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $42.12
Upside: +18.71%
Cytokinetics
Oct 9, 2023
Maintains: Overweight
Price Target: $59 → $65
Current: $65.34
Upside: -0.52%
Solid Biosciences
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $8.98
Upside: -44.32%
Seelos Therapeutics
Sep 21, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.29
Upside: -
Vaxart
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.71
Upside: +463.62%
Cybin
Aug 29, 2023
Reiterates: Overweight
Price Target: $3
Current: $0.35
Upside: +757.14%
Lucid Diagnostics
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.68
Upside: +485.57%
Xenon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $40.50
Upside: +43.21%
Mind Medicine (MindMed)
Aug 22, 2023
Reiterates: Overweight
Price Target: $7
Current: $8.52
Upside: -17.84%
Lumos Pharma
Aug 22, 2023
Reiterates: Overweight
Price Target: $10
Current: $2.86
Upside: +249.65%
KalVista Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $20
Current: $10.78
Upside: +85.53%
BioVie
Aug 22, 2023
Reiterates: Overweight
Price Target: $11
Current: $0.48
Upside: +2,168.98%
Clene
Aug 16, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.34
Upside: +1,076.82%
Cardiol Therapeutics
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.79
Upside: +67.60%
Anavex Life Sciences
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $3.44
Upside: +219.77%
Fennec Pharmaceuticals
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $9.21
Upside: +30.29%
Cognition Therapeutics
Sep 29, 2022
Initiates: Overweight
Price Target: $12
Current: $1.95
Upside: +515.38%
Novavax
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $4.09
Upside: +4,007.58%
Oramed Pharmaceuticals
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.46
Upside: +713.01%
vTv Therapeutics
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $26.97
Upside: +641.70%
Bionomics
Jan 10, 2022
Initiates: Overweight
Price Target: $52
Current: $1.00
Upside: +5,100.00%
Ovid Therapeutics
Apr 20, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.10
Upside: -
Cassava Sciences
Oct 23, 2020
Initiates: Overweight
Price Target: n/a
Current: $22.34
Upside: -
Inovio Pharmaceuticals
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $10.57
Upside: +1,262.35%
Geron
Jun 1, 2020
Maintains: Overweight
Price Target: n/a
Current: $3.79
Upside: -
Halozyme Therapeutics
May 4, 2020
Reiterates: Overweight
Price Target: n/a
Current: $38.57
Upside: -
Cara Therapeutics
Apr 22, 2020
Reiterates: Overweight
Price Target: n/a
Current: $0.68
Upside: -
Corcept Therapeutics
Feb 1, 2019
Downgrades: Neutral
Price Target: n/a
Current: $22.80
Upside: -
Vanda Pharmaceuticals
Aug 23, 2018
Initiates: Neutral
Price Target: n/a
Current: $4.62
Upside: -
Sangamo Therapeutics
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.52
Upside: -
Altimmune
Oct 9, 2017
Initiates: Overweight
Price Target: n/a
Current: $7.26
Upside: -